David John Nutt
Overview
Explore the profile of David John Nutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thurgur H, Lynskey M, Schlag A, Croser C, Nutt D, Iveson E
Br J Clin Pharmacol
. 2024 Jul;
PMID: 38967104
No abstract available.
2.
Belelli D, Riva A, Nutt D
Int Rev Neurobiol
. 2024 Mar;
175:241-276.
PMID: 38555118
The health risks and harm associated with regular alcohol consumption are well documented. In a recent WHO statement published in The Lancet Public Health alcohol consumption has been estimated to...
3.
de Bejczy A, Addolorato G, Aubin H, Guiraud J, Korpi E, Nutt D, et al.
Int Rev Neurobiol
. 2024 Mar;
175:1-19.
PMID: 38555113
Alcohol is a major cause of pre-mature death and individual suffering worldwide, and the importance of diagnosing and treating AUD cannot be overstated. Given the global burden and the high...
4.
Thurgur H, Lynskey M, Schlag A, Croser C, Nutt D, Iveson E
Br J Clin Pharmacol
. 2023 Dec;
90(4):1081-1093.
PMID: 38105651
Aims: To conduct a single-arm open-label feasibility trial of the safety and tolerability of a full-spectrum cannabidiol (CBD)-dominant cannabis-based medicinal product for treating the symptoms of long COVID. Methods: The...
5.
Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S, et al.
Front Psychiatry
. 2023 Jun;
14:1183740.
PMID: 37377473
Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a...
6.
Nygart V, Pommerencke L, Haijen E, Kettner H, Kaelen M, Mortensen E, et al.
J Psychopharmacol
. 2022 Aug;
36(8):932-942.
PMID: 35924888
Background: Over the last two decades, a number of studies have highlighted the potential of psychedelic therapy. However, questions remain to what extend these results translate to naturalistic samples, and...
7.
Jefsen O, Hojgaard K, Christiansen S, Elfving B, Nutt D, Wegener G, et al.
Acta Neuropsychiatr
. 2019 May;
31(4):213-219.
PMID: 31106729
Objective: Psilocybin is a serotonin receptor agonist with a therapeutic potential for treatment-resistant depression and other psychiatric illnesses. We investigated whether the administration of psilocybin had an antidepressant-like effect in...
8.
Casajuana Kogel C, Balcells-Olivero M, Lopez-Pelayo H, Miquel L, Teixido L, Colom J, et al.
Drug Alcohol Depend
. 2017 May;
176:109-116.
PMID: 28531767
Objective: Reliable data on cannabis quantities is required to improve assessment of cannabis consumption for epidemiological analysis and clinical assessment, consequently a Standard Joint Unit (SJU) based on quantity of...
9.
Carhart-Harris R, Nutt D
J Psychoactive Drugs
. 2014 Jan;
45(4):322-8.
PMID: 24377171
A web-based survey was used to consult the opinions of experienced drug users on matters related to drug harms. We identified a rare sample of 93 drug users with personal...